Key Takeaways

• Fermelanta, a Japanese startup, uses a multi-gene platform to produce complex plant compounds through microbial fermentation.
• The company has introduced nearly 30 plant genes into a single bacterial strain, allowing for efficient production of rare ingredients.
• Fermelanta aims to provide solutions for essential medicines and is open to collaborations in food, nutraceuticals, and cosmetics.

Innovative Approach to Ingredient Production

Fermelanta, a Japanese startup founded in 2022, is pioneering a method to efficiently produce complex plant compounds using microbial fermentation. The company, led by CEO Shogo Fukizaki and Business Development Manager Lucas Mixich, PhD, showcased its technology at the Future Food-Tech conference in San Francisco.

Fermelanta’s goal is to streamline the production of both existing and new ingredients, providing cost-effective solutions to industries that previously lacked access to specific natural ingredients. To achieve this, they have succeeded in introducing almost 30 different plant genes into a single E. coli strain. This innovative approach allows for a single fermentation step, significantly enhancing efficiency compared to traditional methods that often require multiple steps.

By utilizing a proprietary tool that enables the introduction of numerous genes, Fermelanta can produce complex metabolites that are typically challenging to create. Unlike existing technologies which are limited to simple molecules requiring one or two genes, Fermelanta’s platform expands the capability to produce a broader range of molecules essential for various applications.

The startup initially aimed at creating rare ingredients for essential medicines like morphine, leveraging over 20 years of accumulated academic research. However, it has recently identified growing market interest in producing high-value ingredients for other sectors, including food, nutraceuticals, and cosmetics. The team is open to collaborations with companies seeking innovative, natural solutions due to high production costs of these ingredients.

One common question about Fermelanta’s approach is why not rely on plant cell cultures for producing these ingredients. While this might seem logical, Mixich explains that plant cells grow slowly and make production processes inefficient. In contrast, the E. coli strains utilized by Fermelanta grow rapidly and are cost-effective to culture, making them an ideal production platform.

Fermelanta’s foundation is built on extensive experience in engineering bacterial strains. Although the company may be new, it implements decades of research focused on manipulating E. coli to optimize their behavior for effective ingredient production.

As Fermelanta continues to develop its technology, the potential to reshape industries—from essential medicines to flavors and fragrances—remains substantial. The startup stands ready to unlock new natural ingredients at scale, thereby addressing both current market demands and facilitating collaborations with various sectors.

The content above is a summary. For more details, see the source article.